Navigation Links
WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
Date:7/11/2008

SHANGHAI, China, July 11 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has won the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. The Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology is awarded to the company that has demonstrated commendable success in forming strategic partnerships with global clients for outsourced laboratory and research manufacturing services in drug discovery and development in pharmaceuticals and biotechnology.

Quality of scientists and personnel, service portfolio, quality of services, speed of service delivery, cost competitiveness, past experience and referrals are the selection criteria that Frost & Sullivan used. According to Frost & Sullivan, WuXi has excelled in the delivery of high-quality services in a timely manner and at competitive costs through a team of proficient scientists supported by world-class management.

"Until January, 2008, WuXi PharmaTech had provided services to more than 700 global clients, with coverage of pharmaceutical, biotechnology and medical devices. High proportion of repeat and referral customers is a testament to its focus on customer satisfaction and operation excellence," said Frost & Sullivan Leader of China Healthcare Operation Mr. Xuchao Hou. "The main contributing fact
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
2. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
3. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
4. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
5. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
6. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
7. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
8. WuXi PharmaTech Announces First Quarter 2008 Results
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
10. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
11. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Dana-Farber ... Cancer Science and Resolution Bioscience, Inc. today announced ... co-develop a novel, blood-based, clinic ready, Next Generation ... (NSCLC). The collaboration is the first to demonstrate ... and ROS1 fusions in blinded plasma samples and ...
(Date:4/16/2015)... CCI Global Channel Management, the world’s leading provider ... for major tech and telecom vendors, has released the ... vendor programs in software, hardware, and telecommunications industries. , ... top IT vendors in each segment focus their channel ... Assessment of the state of channel marketing ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... Feb. 16, 2011 Pneumococcus ( Streptococcus pneumoniae ... of mortality in young children worldwide. While successful ... only work against specific pneumococcal strains, with the ... emerge. Through a novel discovery approach, researchers at ...
... Feb. 16, 2011 Chimerix, Inc., a pharmaceutical company ... has been awarded a contract by the Biomedical Advanced ... of Chimerix,s broad spectrum antiviral drug candidate, CMX001, as ... release. CMX001 is a potential dual-use ...
... DIEGO, Feb. 16, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... a public offering of 6,900,000 shares of its common ... exercise of an overallotment option previously granted to the ... price of $11.25 per share, resulting in aggregate gross ...
Cached Biology Technology:New Pneumococcal Vaccine Approach Successful in Early Tests 2New Pneumococcal Vaccine Approach Successful in Early Tests 3New Pneumococcal Vaccine Approach Successful in Early Tests 4Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 2Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 4Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock 2Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock 3
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... a serious influenza outbreak will do little to hold back ... a study conducted at the UK Health Protection Agency and ... new type of influeza virus appears that causes an illness ... flu. This happened, for example, in 1918, when a flu ...
... For the first time, scientists have defined the collective genome ... microbes, representing more than 1,000 species, make up a motley ... eat, including some vitamins, sugars, and fiber. , In ... Science , scientists at The Institute for Genomic Research (TIGR) ...
... $21 billion for HIV/AIDS research, treatment, prevention, and related ... published in the July 1 issue of The Journal ... is--and more so than previously thought. , The study, ... MD, MSc and colleagues at Massachusetts General Hospital and ...
Cached Biology News:Air travel and pandemic flu 2Gut reaction: Researchers define the colon's genome 2Gut reaction: Researchers define the colon's genome 3New study calculates millions of years saved in lives of AIDS patients 2
... is produced by a patented microwave process ... more consistent, even cell attachment, increased cell ... and growth uunder difficult conditions, including reduced ... provide a more ecominic alternative to expensive ...
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Cell Culture Flask, 75 cm, treated polystyrene...
Cell Culture Flask, 75 cm, nontreated polystyrene...
Biology Products: